GlobalData sees bipolar disorder market accelerating

The bipolar disorder market across the USA, Europe, and Japan is forecast to rise from $5.6 billion in 2024 to $9.4 billion in 2034, according to GlobalData. The 5.3% growth rate reflects higher diagnosed prevalence and the emergence of six late-stage therapies expected to reshape prescribing.

Global estimates place the wider bipolar disorder market at around $5–10 billion, depending on methodology. Analysts expect steady growth through the decade as mental health awareness improves and more patients enter formal care pathways, creating room for differentiated new entrants despite widespread generic use.

Growth is expected to be driven by late-stage candidates azetukalner, Bysanti (milsaperidone), Cyclurad (cycloserine and lurasidone), NRX-100 (ketamine hydrochloride), endoxifen, and Cobenfy (trospium chloride and xanomeline). Combined sales of roughly $2.8 billion are projected by 2034, with four agents targeting bipolar depression.